 Shares in GenMark Diagnostics GNMK are soaring 10 in Wednesdays pre-market trading after the molecular diagnostics company announced impressive preliminary financial and operational results for the quarter ended June 30, 2020 due to strong sales of COVID-19 test sales.Second quarter revenue is now expected to be approximately 40.1 million, an increase of 118 over the second quarter of 2019. GNMK is now anticipating ePlex revenue of 35.2 million, up 195 year-over-year.COVID-19 positively impacted second quarter placements and revenue, the company stated, with approximately 90 of gross placements including interest in COVID-19 testing.GenMark also revealed that SARS-CoV-2 consumable revenue accounted for approximately 48 of total ePlex revenue.Gross margin is now expected to be approximately 38 to 39, compared to 36 in the second quarter of 2019.During the quarter, the company placed net 71 ePlex analyzers, concluding the quarter with a global installed base of more than 650 ePlex analyzers, an increase of 48 from the same period last year.Strong COVID-19 demand continued to drive additional ePlex placements, which provides the foundation for future recurring testing revenues across our broader menu commented CEO Scott Mendel.In addition, we launched our RP2 Panel, which incorporates SARS-CoV-2 onto our existing syndromic panel for respiratory pathogen testing. The RP2 panel also introduces a simplified workflow, making it even easier for hospital labs to run our test he added.The GenMark ePlex SARS-CoV-2 Test and ePlex RP2 Panel have been made available under an emergency access mechanism called an Emergency Use Authorization EUA.GNMK has rallied 224 year-to-date, and analysts have a bullish Strong Buy consensus on the stocks outlook. However, thanks to the recent rally, the average analyst price target now indicates downside potential of 7 from current levels. See GenMark stock analysis on TipRanks.The GNMK story has changed over the past 6 months, and we believe the stocks 5.3x forward sales multiple doesnt fully reflect the companys 1 growth prospects, 2 improving competitive position and 3 upgraded installed base quantity and quality of customers Canaccord Genuitys Max Masucci recently told investors. He has a buy rating on the stock and 17 price target.Related News: Novavax Spikes 42 Pre-Market On 1.6B U.S. Funding For Covid-19 Candidate Corvus Shoots Up 115 On Start Of Novel Immunotherapy Study In Covid-19 Patients Regeneron Up 5 In Pre-Market On Start Of Late-Stage Covid-19 Antibody Trial More recent articles from Smarter Analyst: Philip Morris Scores FDA Approval For Modified Risk Labeling Avolon Cancels 27 Of Boeing 737 Max Aircraft Order TechnipFMC Spikes 11 After-Hours On 1B Egypt Contract AMC Pops 12 In After-Market Amid Report Of New Restructuring Deal To Avert Bankruptcy 